Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation

Br J Haematol. 2018 Jul;182(1):148-152. doi: 10.1111/bjh.14748. Epub 2017 May 9.
No abstract available

Keywords: ETV6-PDGFRB; chronic myeloid leukaemia; imatinib; quantitative reverse transcription-PCR; treatment free remission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Gene Rearrangement*
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / genetics*
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics
  • Male
  • Middle Aged
  • Oncogene Proteins, Fusion / genetics*
  • Real-Time Polymerase Chain Reaction / methods

Substances

  • Antineoplastic Agents
  • ETV6-PDGFRB fusion protein, human
  • Oncogene Proteins, Fusion
  • Imatinib Mesylate